Compositions and methods for treating influenza
View Patent ↗The present disclosure provides compositions and methods useful for treating influenza. As described herein, provided compositions and methods are based on the development of certain compositions that include an influenza virus hemagglutinin antigen in combination with lipid vesicles that include a non-ionic surfactant (NISVs) and optionally an adjuvant. In certain embodiments, provided compositions remain potent even when they are not stored in a standard cold-chain system (i.e., they are thermostable).
1. An immunogenic composition comprising an influenza virus hemagglutinin antigen from at least one of influenza A H1N1 and influenza A H3N2 strain and lipid vesicles, wherein the lipid vesicles comprise lipids that are present in the composition in an amount that achieves a lipid:antigen weight ratio within a range of about 50:1 to about 400:1 and the lipids include a non-ionic surfactant comprising 1-monopalmitoyl glycerol, wherein the composition is more stable when stored for 6 months at 40° C. than a reference composition that lacks the lipid vesicles, and
(i) wherein the composition comprises one or more inactivated influenza viruses that include the influenza virus hemagglutinin antigen,
(ii) wherein the composition comprises one or more attenuated influenza viruses that include the influenza virus hemagglutinin antigen,
(iii) wherein the influenza virus hemagglutinin antigen is present in the composition as a split virus antigen, or
(iv) wherein the influenza virus hemagglutinin antigen is present in the composition as a purified or recombinant subunit antigen.
2. The composition of claim 1 , wherein the composition is a liquid.
3. The composition of claim 1 , wherein the composition is dried.
4. The composition of claim 3 , wherein the lipid vesicles comprise lipids that are present in the composition in an amount that achieves a lipid: antigen weight ratio of at least about 50:1, and the moisture content of the composition is less than about 2% by weight.
5. The composition of claim 1 , wherein the lipid: antigen weight ratio is at least about 100:1.
6. The composition of claim 1 , wherein the lipid: antigen weight ratio is at least about 200:1.
7. The composition of claim 1 , wherein the lipid: antigen weight ratio is at least about 250:1.
8. The composition of claim 1 , wherein the lipid: antigen weight ratio is less than about 350:1.
9. The composition of claim 1 , wherein the lipid: antigen weight ratio is within a range of about 250:1 to about 350:1.
10. The composition of claim 1 , wherein the lipid: antigen weight ratio is about 300:1.
11. The composition of claim 1 , wherein the composition exhibits less than 50% change in immunogenicity as determined by an HAI assay when stored for 6 months at 40° C.
12. The composition of claim 11 , wherein the composition exhibits less than 10% change in immunogenicity.
13. The composition of claim 1 , wherein the composition exhibits less than 50% loss of antigen content as determined by an ELISA when stored for 6 months at 40° C.
14. The composition of claim 13 , wherein the composition exhibits less than 10% loss of antigen content.
15. The composition of claim 1 , wherein stability is based on immunogenicity as determined by an HAI assay.
16. The composition of claim 1 , wherein stability is based on antigen content as determined by an ELISA.
17. The composition of claim 1 , wherein the influenza virus hemagglutinin antigen is from an influenza A H1N1 strain.
18. The composition of claim 1 , wherein the influenza virus hemagglutinin antigen is from an influenza A H3N2 strain.
19. The composition of claim 1 , wherein the immunogenic composition further comprises an influenza virus hemagglutinin antigen from an influenza B strain.
20. The composition of claim 19 , wherein the influenza virus hemagglutinin antigen is from two of an influenza A H1N1 strain, an influenza A H3N2 strain and an influenza B strain.
21. The composition of claim 1 , wherein the influenza virus hemagglutinin antigen is from an influenza A H1N1 strain, an influenza A H3N2 strain and combinations of one or both with hemagluttinin antigen from an influenza B strain an influenza B strain.
22. The composition of claim 21 , wherein the composition comprises approximately equal amounts of influenza virus hemagglutinin antigen from each strain.
23. The composition of claim 1 , wherein the lipids further comprise an ionic amphiphile.
24. The composition of claim 23 , wherein the ionic amphiphile is dicetylphosphate.
25. The composition of claim 1 , wherein the lipids further comprise a steroid.
26. The composition of claim 25 , wherein the steroid is cholesterol.
27. The composition of claim 1 , wherein the lipids further comprise an ionic amphiphile and a steroid.
28. The composition of claim 1 , wherein the lipids further comprise dicetylphosphate and cholesterol.
29. The composition of claim 1 , wherein at least a portion of the influenza virus hemagglutinin antigen present in the composition is associated with the lipid vesicles.
30. The composition of claim 1 , wherein at least a portion of the influenza virus hemagglutinin antigen present in the composition is entrapped within the lipid vesicles.
31. The composition of claim 1 , wherein the composition further comprises an adjuvant.
32. The composition of claim 31 , wherein the adjuvant comprises a TLR-4 agonist.
33. The composition of claim 32 , wherein the adjuvant comprises an attenuated lipid A derivative.
34. The composition of claim 32 , wherein the adjuvant comprises a monophosphoryl derivative of lipid A.
35. The composition of claim 32 , wherein the adjuvant comprises a 3-deacyl monophosphoryl derivative of lipid A.
36. The composition of claim 31 , wherein the adjuvant comprises a TLR-7/8 agonist.
37. The composition of claim 31 , wherein the adjuvant comprises a TLR-9 agonist.
38. The composition of claim 31 , wherein at least a portion of the adjuvant present in the composition is associated with the lipid vesicles.
39. The composition of claim 31 , wherein at least a portion of the adjuvant present in the composition is not associated with the lipid vesicles.
40. A method of treating a subject suffering from, or at risk for, an influenza infection, the method comprising:
providing the composition of claim 1 in dried form;
rehydrating the composition; and
administering to the subject a therapeutically effective amount of the rehydrated composition.
41. The method of claim 40 , wherein the rehydrated composition is administered by intramuscular injection.
42. A method of preparing an immunogenic composition comprising an influenza virus hemagglutinin antigen from at least one of influenza A H1N1 strain and influenza A H3N2 strain and lipid vesicles, wherein the lipid vesicles comprise lipids that include a non-ionic surfactant comprising 1-monopalmitoyl glycerol, wherein the composition is more stable when stored for 6 months at 40° C. than a reference composition that lacks the lipid vesicles, the method comprising:
melting the lipids to produce molten lipids;
combining the molten lipids with an aqueous solution that includes the influenza virus hemagglutinin antigen; and
homogenizing the resulting product, wherein the molten lipids and aqueous solution are combined in relative amounts that achieve a lipid:antigen weight ratio of at least about 50:1 in the resulting product.
43. The method of claim 42 , wherein the molten lipids and aqueous solution are combined in relative amounts that achieve a lipid: antigen weight ratio of at least about 100:1 in the resulting product.
44. The method of claim 42 , wherein the molten lipids and aqueous solution are combined in relative amounts that achieve a lipid: antigen weight ratio of at least about 200:1 in the resulting product.
45. The method of claim 42 , wherein the molten lipids and aqueous solution are combined in relative amounts that achieve a lipid: antigen weight ratio of at least about 250:1 in the resulting product.
46. The method of claim 42 , wherein the molten lipids and aqueous solution are combined in relative amounts that achieve a lipid: antigen weight ratio of less than about 400:1 in the resulting product.
47. The method of claim 42 , wherein the molten lipids and aqueous solution are combined in relative amounts that achieve a lipid:antigen weight ratio of less than about 350:1 in the resulting product.
48. The method of claim 42 , wherein the molten lipids and aqueous solution are combined in relative amounts that achieve a lipid:antigen weight ratio within a range of about 250:1 to about 350:1 in the resulting product.
49. The method of claim 42 , wherein the molten lipids and aqueous solution are combined in relative amounts that achieve a lipid:antigen weight ratio of about 300:1 in the resulting product.
50. The method of claim 42 , wherein the molten lipids are added to the aqueous solution that includes the influenza virus hemagglutinin antigen.
51. The method of claim 42 , wherein the aqueous solution that includes the influenza virus hemagglutinin antigen is added to the molten lipids.
52. A method of preparing an immunogenic composition comprising an influenza virus hemagglutinin antigen from at least one of influenza A H1N1 strain and influenza A H3N2 strain and lipid vesicles, wherein the lipid vesicles comprise lipids that include a non-ionic surfactant comprising 1-monopalmitoyl glycerol, wherein the composition is more stable when stored for 6 months at 40° C. than a reference composition that lacks the lipid vesicles, the method comprising:
melting the lipids to produce molten lipids;
combining the molten lipids with an aqueous solution that includes the influenza virus hemagglutinin antigen; and
homogenizing the resulting product, wherein the molten lipids and aqueous solution are combined in relative amounts and volumes that achieve a lipid concentration of at least about 10 mg/ml in the resulting product.
53. The method of claim 52 , wherein the molten lipids and aqueous solution are combined in relative amounts and volumes that achieve a lipid concentration in a range of about 10 mg/ml to about 100 mg/ml in the resulting product.
54. The method of claim 52 , wherein the molten lipids and aqueous solution are combined in relative amounts that achieve a lipid: antigen weight ratio of at least about 50:1 in the resulting product.
55. The method of claim 54 , wherein the molten lipids and aqueous solution are combined in relative amounts that achieve a lipid:antigen weight ratio of at least about 100:1 in the resulting product.
56. The method of claim 54 , wherein the molten lipids and aqueous solution are combined in relative amounts that achieve a lipid:antigen weight ratio of at least about 200:1 in the resulting product.
57. The method of claim 54 , wherein the molten lipids and aqueous solution are combined in relative amounts that achieve a lipid:antigen weight ratio of at least about 250:1 in the resulting product.
58. The method of claim 54 , wherein the molten lipids and aqueous solution are combined in relative amounts that achieve a lipid:antigen weight ratio of less than about 400:1 in the resulting product.
59. The method of claim 54 , wherein the molten lipids and aqueous solution are combined in relative amounts that achieve a lipid:antigen weight ratio of less than about 350:1 in the resulting product.
60. The method of claim 54 , wherein the molten lipids and aqueous solution are combined in relative amounts that achieve a lipid:antigen weight ratio within a range of about 250:1 to about 350:1 in the resulting product.
61. The method of claim 54 , wherein the molten lipids and aqueous solution are combined in relative amounts that achieve a lipid:antigen weight ratio of about 300:1 in the resulting product.
62. The method of claim 52 , wherein the molten lipids are added to the aqueous solution that includes the influenza virus hemagglutinin antigen.
63. The method of claim 52 , wherein the aqueous solution that includes the influenza virus hemagglutinin antigen is added to the molten lipids.